Compare Stocks: MTNB, SNTI, CMMB, and OTLC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$1.38 -0.7%	$2.13	$1.05 ▼ $3.50	$10.07M	0.74	150,403 shs	12,203 shs
MTNB Matinas Biopharma	$2.87 +1.4%	$3.03	$2.26 ▼ $28.95	$2.77M	2.08	142,341 shs	35,267 shs
OTLC Oncotelic Therapeutics	$0.02 -1.0%	$0.03	$0.02 ▼ $0.11	$9.59M	-0.18	425,492 shs	480,132 shs
SNTI Senti Biosciences	$0.31 -2.3%	$0.35	$0.29 ▼ $2.88	$10.02M	2.21	1.20 million shs	109,926 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	-0.72%	-3.50%	-48.70%	-20.69%	-60.57%
MTNB Matinas Biopharma	+1.41%	+8.71%	+4.16%	-74.67%	-89.77%
OTLC Oncotelic Therapeutics	-0.95%	-0.95%	-31.35%	-46.39%	-76.86%
SNTI Senti Biosciences	-2.27%	-2.45%	+5.15%	-69.48%	-82.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$1.38 -0.7%	$2.13	$1.05 ▼ $3.50	$10.07M	0.74	150,403 shs	12,203 shs
MTNB Matinas Biopharma	$2.87 +1.4%	$3.03	$2.26 ▼ $28.95	$2.77M	2.08	142,341 shs	35,267 shs
OTLC Oncotelic Therapeutics	$0.02 -1.0%	$0.03	$0.02 ▼ $0.11	$9.59M	-0.18	425,492 shs	480,132 shs
SNTI Senti Biosciences	$0.31 -2.3%	$0.35	$0.29 ▼ $2.88	$10.02M	2.21	1.20 million shs	109,926 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	-0.72%	-3.50%	-48.70%	-20.69%	-60.57%
MTNB Matinas Biopharma	+1.41%	+8.71%	+4.16%	-74.67%	-89.77%
OTLC Oncotelic Therapeutics	-0.95%	-0.95%	-31.35%	-46.39%	-76.86%
SNTI Senti Biosciences	-2.27%	-2.45%	+5.15%	-69.48%	-82.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	1.50	Reduce	N/A	N/A
MTNB Matinas Biopharma	0.00	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	0.00	N/A	N/A	N/A
SNTI Senti Biosciences	2.75	Moderate Buy	$10.00	3,080.66% Upside

Current Analyst Ratings Breakdown

Latest MTNB, SNTI, CMMB, and OTLC Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/16/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	SNTI Senti Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.00 per share	N/A
MTNB Matinas Biopharma	$1.10M	2.56	N/A	N/A	$11.30 per share	0.25
OTLC Oncotelic Therapeutics	$70K	135.64	$0.52 per share	0.04	$0.59 per share	0.04
SNTI Senti Biosciences	$55K	178.04	N/A	N/A	$0.18 per share	1.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$8.99M	-$2.13	N/A	N/A	N/A	N/A	-92.14%	-82.05%	11/6/2026 (Estimated)
MTNB Matinas Biopharma	-$10.35M	-$3.89	N/A	N/A	N/A	N/A	-166.11%	-102.20%	N/A
OTLC Oncotelic Therapeutics	$249.28M	$0.59	0.04	N/A	N/A	N/A	123.75%	81.36%	N/A
SNTI Senti Biosciences	-$61.44M	-$1.77	N/A	N/A	N/A	N/A	-1,629.80%	-119.72%	11/12/2026 (Estimated)

Latest MTNB, SNTI, CMMB, and OTLC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	CMMB Chemomab Therapeutics	-$0.01	N/A	N/A	N/A	N/A	N/A
8/20/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.15	-$0.27	-$0.12	-$0.24	N/A	N/A
8/14/2026	Q2 2026	SNTI Senti Biosciences	-$0.33	-$0.41	-$0.08	-$0.41	N/A	$0.02 million
8/13/2026	Q2 2026	MTNB Matinas Biopharma	N/A	-$3.15	N/A	-$3.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	6.41	6.41
MTNB Matinas Biopharma	N/A	0.85	0.85
OTLC Oncotelic Therapeutics	0.01	0.08	0.08
SNTI Senti Biosciences	N/A	0.83	0.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
MTNB Matinas Biopharma	11.77%
OTLC Oncotelic Therapeutics	N/A
SNTI Senti Biosciences	25.70%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
MTNB Matinas Biopharma	4.60%
OTLC Oncotelic Therapeutics	39.22%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	12	7.25 million	6.38 million	Not Optionable
MTNB Matinas Biopharma	2	980,000	935,000	N/A
OTLC Oncotelic Therapeutics	20	456.49 million	277.46 million	Not Optionable
SNTI Senti Biosciences	39	31.15 million	30.17 million	Not Optionable

MTNB, SNTI, CMMB, and OTLC Headlines

Recent News About These Companies

Reviewing Senti Biosciences (NASDAQ:SNTI) & Regeneron Pharmaceuticals (NASDAQ:REGN)

October 7 at 3:58 AM | americanbankingnews.com

Senti Biosciences Holdings Inc

August 11, 2026 | cnn.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...

July 15, 2026 | markets.businessinsider.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

July 15, 2026 | globenewswire.com

Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure

May 16, 2026 | tipranks.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...

May 14, 2026 | markets.businessinsider.com $https://markets.businessinsider.com/news/stocks/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-and-durability-1036155933$

Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia

May 14, 2026 | quiverquant.comQ

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

May 14, 2026 | globenewswire.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

May 14, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/05/14/3294958/0/en/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-an.html$

Senti Biosciences Holdings Inc.

May 13, 2026 | barrons.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | markets.businessinsider.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | globenewswire.com

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

April 1, 2026 | globenewswire.com

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 27, 2026 | globenewswire.com

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

March 23, 2026 | globenewswire.com

Senti Biosciences Amends Lease, Restructures GeneFab Sublease

March 19, 2026 | tipranks.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | tmcnet.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | globenewswire.com

Senti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care Conference

February 24, 2026 | quiverquant.comQ

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

February 24, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, SNTI, CMMB, and OTLC Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$1.38 -0.01 (-0.72%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.38 0.00 (0.00%)

As of 10/9/2026 04:46 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Matinas Biopharma NYSEAMERICAN:MTNB

$2.87 +0.04 (+1.41%)

As of 10/9/2026 04:10 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Oncotelic Therapeutics OTCMKTS:OTLC

$0.02 0.00 (-0.95%)

As of 10/9/2026 03:16 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Senti Biosciences NASDAQ:SNTI

$0.31 -0.01 (-2.27%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.31 0.00 (-0.13%)

As of 10/9/2026 07:59 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTNB, SNTI, CMMB, and OTLC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTNB, SNTI, CMMB, and OTLC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTNB, SNTI, CMMB, and OTLC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, SNTI, CMMB, and OTLC Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

Matinas Biopharma NYSEAMERICAN:MTNB

Oncotelic Therapeutics OTCMKTS:OTLC

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTNB, SNTI, CMMB, and OTLC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTNB, SNTI, CMMB, and OTLC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTNB, SNTI, CMMB, and OTLC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTNB, SNTI, CMMB, and OTLC Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

Matinas Biopharma NYSEAMERICAN:MTNB

Oncotelic Therapeutics OTCMKTS:OTLC

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools